Research Paper Volume 16, Issue 10 pp 9047—9071
Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma
Figure 5. Exploration of the potential mechanism of PCDI. (A) Bar plot illustrating the correlation between immunomodulators and PCDI in the TCGA dataset. (B) GO enrichment analysis of immune response-related pathways in the two PCDI groups. (C) KEGG enrichment analysis of immune response-related pathways in the two PCDI groups. (D) Gene set enrichment analysis (GSEA) highlighting hallmark pathways in the two PCDI groups. (E) Correlation analysis between the fraction of activated Mast cells calculated by CIBERSORT and PCDI in the TCGA and GSE14520 datasets. (*P < 0.05, **P < 0.01, and ***P < 0.001 determined by Wilcoxon test).